Coherus-JPM-20240110 .pdf

1、Denny Lanfear,Chief Executive OfficerJanuary 10,2024J.P.Morgan Annual Healthcare Conference 2024 Coherus BioSciences.Forward Looking StatementsForward Looking Statements-Except for the historical information discussed today and contained herein,the matters discussed today and set forth in this prese

2、ntation are forward-looking statements within the meaning of the“safe harbor”provisions of the Private Securities Litigation Reform Act of 1995,including,but not limited to,statements regarding partnerships and collaborations that may maximize value;expectations for the launch timing for UDENYCA OBI

3、;our expectations for share,opportunity,demand and payer coverage all increasing for UDENYCA;market opportunity projections for LOQTORZI;our ability to reach the full NPC patient population with LOQTORZI;our expectations about HCPs who represent potential targets for LOQTORZI promotion;our expectati

4、ons for the efficacy of casdozokitug or our other product candidates;our expectations that combinations with our internal pipeline and external collaborators will unlock value;expectations about the timing or ability to achieve future catalysts with our pipeline product candidates,including filing a

5、n IND for CHS-1000 and obtaining phase 1 data for CHS-114;and our ability to realize financial contributions and revenues from CIMERLI and YUSIMRY in 2024 and future years.Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus actual results,performance

6、or achievements to differ significantly from any future results,performance or achievements expressed or implied by the forward-looking statements.Such risks and uncertainties include,among others,the risks and uncertainties caused by our transition from a biosimilar focused company to an innovative